Nifedipine not superior to placebo for chronic chilblains

Nifedipine not superior to placebo for chronic chilblains
(HealthDay)—For patients with chronic chilblains, nifedipine is not superior to placebo, according to a study published in the September/October issue of the Annals of Family Medicine.

Ibo H. Souwer, M.D., from the Radboud University Medical Center in the Netherlands, and colleagues conducted a involving 32 patients with chronic chilblains. Participants were randomized to nifedipine (30 mg controlled release twice daily) or placebo.

After six weeks of treatment, the researchers found that in mean scores on the visual analogue scale on complaints, there was a nonsignificant difference of 1.84 mm in favor of nifedipine. There was a nonsignificant difference of 0.56 mm in favor of placebo in mean scores on the visual analogue scale on disability. No carry-over effect was seen from prior study treatment. There was a correlation for nifedipine with significantly lower systolic blood pressure and a significantly higher incidence of edema.

"In our study, nifedipine was not superior to for treating chronic chilblains," the authors write. "These findings contrast with those of the older study and do not support routine use of nifedipine for this condition."


Explore further

Nifedipine-maintained tocolysis no benefit in perinatal outcomes

More information: Abstract
Full Text
Journal information: Annals of Family Medicine

Copyright © 2016 HealthDay. All rights reserved.

Citation: Nifedipine not superior to placebo for chronic chilblains (2016, September 16) retrieved 16 June 2019 from https://medicalxpress.com/news/2016-09-nifedipine-superior-placebo-chronic-chilblains.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
0 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more